Article info
PDFClinical and epidemiological research
Concise report
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study
- Correspondence to Professor Valerie Devauchelle, Rheumatology Unit, Hôpital de la Cavale Blanche, BP 824, Brest cedex F 29609, France; valerie.devauchelle-pensec{at}chu-brest.fr
Citation
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study
Publication history
- Received October 8, 2015
- Revised January 6, 2016
- Accepted January 22, 2016
- First published February 29, 2016.
Online issue publication
July 08, 2016
Article Versions
- Previous version (29 February 2016).
- Previous version (24 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/